Publications by authors named "Joel Morganroth"

35Publications

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.

Clin Pharmacol Drug Dev 2019 01 22;8(1):49-59. Epub 2018 May 22.

eResearch Technology, Inc, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.442DOI Listing
January 2019

Benefits of Centralized ECG Reading in Clinical Oncology Studies.

Ther Innov Regul Sci 2016 Jan;50(1):123-129

1 EResearch Technology Inc, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2168479015597729DOI Listing
January 2016

Replacing the thorough QT study: reflections of a baby in the bath water.

Br J Clin Pharmacol 2014 Aug;78(2):195-201

eResearch Technology, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.12296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137815PMC
August 2014

Electrocardiographic response to intravenous and intraarterial injection of iosimenol (a new, iodinated, non-ionic, iso-osmolar contrast medium).

J Invasive Cardiol 2013 Nov;25(11):573-8

Otsuka Pharmaceutical Development & Commercialization, Inc, 1 University Square Drive, Suite 500 Princeton, NJ 08540 USA.

View Article

Download full-text PDF

Source
November 2013

Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Drug Saf 2013 Jun;36(6):413-26

Rashmi Shah Consultancy Ltd, Birchdale, Gerrards Cross, Buckinghamshire SL9 7JA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-013-0050-xDOI Listing
June 2013

Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Drug Saf 2013 Jul;36(7):491-503

Rashmi Shah Consultancy Ltd, 8 Birchdale, Gerrards Cross, Buckinghamshire, SL9 7JA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-013-0048-4DOI Listing
July 2013

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Drug Saf 2013 May;36(5):295-316

Rashmi Shah Consultancy Ltd., 8 Birchdale, Gerrards Cross, Buckinghamshire SL9 7JA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-013-0047-5DOI Listing
May 2013

Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?

Drug Saf 2013 Mar;36(3):167-82

Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, US FDA, Silver Spring, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-013-0016-zDOI Listing
March 2013

Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.

Expert Opin Pharmacother 2013 Jan 10;14(1):5-13. Epub 2012 Dec 10.

eResearch Technology, Inc., Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2013.753057DOI Listing
January 2013

ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.

Br J Clin Pharmacol 2013 Apr;75(4):959-65

Rashmi Shah Consultancy Ltd, Gerrards Cross, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2012.04442.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612714PMC
April 2013

Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Drug Saf 2012 Sep;35(9):695-709

Rashmi Shah Consultancy Ltd, Gerrards Cross, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF03261967DOI Listing
September 2012

Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile.

Reg Anesth Pain Med 2012 Mar-Apr;37(2):145-51

Department of Anesthesiology, Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00115550-201203000-000
Publisher Site
http://dx.doi.org/10.1097/AAP.0b013e31823d0a80DOI Listing
September 2012

Proarrhythmic potential of reverse use-dependent drugs.

J Electrocardiol 2007 Sep-Oct;40(5):432-3. Epub 2007 May 24.

eResearch Technology, Inc, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jelectrocard.2007.03.243DOI Listing
September 2007

Eletrocardiographic monitoring in COPD patients receiving tiotropium.

COPD 2004 ;1(2):181-90

University of Pennsylvania, eResearch Technology, Inc., Gladwyne, Pennsylvania 19035, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/copd-120039560DOI Listing
December 2006

Evaluation of vardenafil and sildenafil on cardiac repolarization.

Am J Cardiol 2004 Jun;93(11):1378-83, A6

University of Pennsylvania School of Medicine and eResearchTechnology Inc., Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2004.02.034DOI Listing
June 2004

A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment.

Authors:
Joel Morganroth

J Electrocardiol 2004 Jan;37(1):25-9

eResearch Technology, Inc., Philadelphia, PA 19103-4001, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jelectrocard.2003.11.004DOI Listing
January 2004

Clinical experience with moxifloxacin in patients with respiratory tract infections.

Ann Pharmacother 2004 May 16;38(5):749-54. Epub 2004 Mar 16.

Pharmaceutical Safety Assessments, Inc., Narberth, PA 19072-2156, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1345/aph.1C066DOI Listing
May 2004

Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parameters.

J Electrocardiol 2003 ;36 Suppl:115-20

Cardiology Unit, Heart Research Follow-up Program, University of Rochester, NY 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jelectrocard.2003.09.034DOI Listing
April 2004

Electrocardiographic effects of rivastigmine.

J Clin Pharmacol 2002 May;42(5):558-68

eResearch Technology, Philadelphia, PA 19103, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/00912700222011490DOI Listing
May 2002

The pharmacokinetics and safety of single escalating oral doses of eletriptan.

J Clin Pharmacol 2002 May;42(5):520-7

Pfizer Central Research Division, Groton, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/00912700222011571DOI Listing
May 2002